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ABSTRACT
Satellite cells are myogenic precursors that proliferate,
activate, and differentiate on muscle injury to sustain the
regenerative capacity of adult skeletal muscle; in this pro-
cess, they self-renew through the return to quiescence of
the cycling progeny. This mechanism, while efﬁcient in
physiological conditions does not prevent exhaustion of
satellite cells in pathologies such as muscular dystrophy
where numerous rounds of damage occur. Here, we
describe a key role of nitric oxide, an important signaling
molecule in adult skeletal muscle, on satellite cells mainte-
nance, studied ex vivo on isolated myoﬁbers and in vivo
using the a-sarcoglycan null mouse model of dystrophy
and a cardiotoxin-induced model of repetitive damage. Ni-
tric oxide stimulated satellite cells proliferation in a path-
way dependent on cGMP generation. Furthermore, it
increased the number of Pax7
1/Myf5
2 cells in a cGMP-in-
dependent pathway requiring enhanced expression of
Vangl2, a member of the planar cell polarity pathway
involved in the Wnt noncanonical pathway. The enhanced
self-renewal ability of satellite cells induced by nitric oxide
is sufﬁcient to delay the reduction of the satellite cell pool
during repetitive acute and chronic damages, favoring
muscle regeneration; in the a-sarcoglycan null dystrophic
mouse, it also slowed disease progression persistently.
These results identify nitric oxide as a key messenger in
satellite cells maintenance, expand the signiﬁcance of the
Vangl2-dependent Wnt noncanonical pathway in myogene-
sis, and indicate novel strategies to optimize nitric oxide-
based therapies for muscular dystrophy. STEM CELLS
2012;30:197–209
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INTRODUCTION
The ability of postnatal skeletal muscle to continuously regen-
erate its ﬁbers is mostly dependent on satellite cells (SCs),
myogenic precursors located under the basal lamina of myo-
ﬁbers, although other interstitial stem cells recently described
may also play a role [1]. SC activate and differentiate on
injury and are characterized by reversible quiescence and self-
renewal capacities that are critical to sustain tissue regenera-
tion during numerous rounds of damage [2–4]. The state of
quiescence is characterized by the persistence of a G0 phase,
the expression of several markers including M-Cadherin, Syn-
decans 3 and 4, CD34, a-7 integrin, SMC 2.6 [5–8], the
expression of the paired-box protein Pax7, a regulator of cell
survival and myogenic progression, and by the concomitant
lack of expression of myogenic determination genes [9, 10].
On activation, SC proliferate and give rise to a population of
myoblasts expressing myogenic regulatory factors which
includes Myf5; these cells progressively downregulate Pax7
and, after multiple rounds of cell division, terminally differen-
tiate to ﬁnally fuse and generate new ﬁbers [11, 12]. A subset
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cence by both symmetric and asymmetric divisions [13, 14].
This ‘‘reserve cell’’ pool is particularly relevant as it is the
one accounting physiologically for muscle repair throughout
life span. The importance to possess a SC renewable pool and
thus an efﬁcient muscle repair mechanism emerges clearly in
muscular dystrophies, where genetic alterations in genes cod-
ing for structural muscle proteins lead to repeated and
enhanced muscle damage during physiological activity.
Although in initial phases of the disease the activity of SC
may repair muscle damage, with time the myogenic precursor
cell pool is progressively exhausted leading to a ﬁbrotic and
dysfunctional muscle [15].
Several factors involved in SC self-renewal have now
been identiﬁed, including Myostatin/Smad3 [16–18], Angio-
poietin1/Tie2 [19], Sprouty [20], Syndecan-3/Notch [21],
Notch/Delta1, and Numb [4, 13, 22, 23]. Recent studies have
also identiﬁed the key role of members of the canonical/b-
catenin (b-Cat)-dependent and of the noncanonical Wnt path-
ways, the latter involving Wnt7a, its receptor Frizzled7 (Fzd7)
and Vangl2, the mammalian homolog of the Drosophila
Vangl2/Stbm [24–31]. Despite these studies, strategies to main-
tain SC renewal that can be exploited in a therapeutic perspec-
tive for muscular dystrophy are still lacking.
Here, we demonstrate that nitric oxide (NO), a key signal-
ing molecule that controls adult skeletal muscle structure, bio-
energetics, and function [32–34], and whose generation is
altered in dystrophic muscles [35–38], maintains and regener-
ates the SC reserve pool. NO stimulates proliferation of SC
and maintains the pool of Pax7
þ/Myf5
  SC following chronic
and acute repetitive muscle injuries. NO stimulates prolifera-
tion of SC via cyclic GMP (cGMP) generation while the
maintenance of the pool of Pax7
þMyf5
  SC depends on the
Vangl2-dependent Wnt noncanonical pathway. In addition, we
identify in molsidomine, a NO releasing drug approved for
use in humans, a very promising NO donating system
endowed with great efﬁcacy that may be successfully devel-
oped as a therapeutic for muscular dystrophies.
MATERIALS AND METHODS
Animals and Treatments
a-Sarcoglycan (a-SG) null mice, matched 129S2/SvpasClr control
wild-type mice, C57BL/6J wild-type mice, and neuronal NO syn-
thase (nNOS) null mice were housed in the pathogen-free facility
at our Institution and treated in accordance with the European
Community guidelines and with the approval of the Institutional
Ethical Committee.
Standard diet (STD) or a diet containing 3 mg/kg of
(1-ethoxy-N-(3-morpholino-5-oxadiazol-3-iumyl)methanimidate (mol-
sidomine) was prepared based on the daily food intake measured
for these animals [39]. No signiﬁcant differences in food intake
and weight gain were observed among the experimental groups.
N
xnitro-L-arginine methylester (L-NAME, 1 mg/ml) was adminis-
tered in drinking water.
In the experiments of cardiotoxin (CTX)-induced damage on
wild-type mice (ﬁve animals/group for each experiment aged 6–8
weeks), drug treatments were started 1 week before CTX injec-
tion and continued until sacriﬁce. CTX (50 llo fa1 0lM solu-
tion) was injected using an insulin needle in both the Tibialis
Anterior (TA) and quadriceps muscles. In parallel, two groups of
mice (ﬁve animals per group) were injected with phosphate-
buffered saline (PBS) as control. For the multiple damage experi-
ments, CTX was injected three times every 5 days. The mice
were sacriﬁced 10 days after injury to collect ﬁbers from the
Extensor Digitorum Longus muscle (EDL) or to isolate TA for
histological analysis. When used, 5 bromo-20-deoxyuridine
(BrdU, 50 mg/g of body weight) was injected intraperitoneally,
on day 5 after CTX damage, 2 hours before sacriﬁce.
a-SG null mice (15 animals per group) were treated starting at
1 month of age for up to 9 months. Mice were sacriﬁced at 5 and
9 months of age for histological and single ﬁbers analysis [39].
For embryo studies, drug treatments of female a-SG null
mice were started a week before and were maintained during the
gestation period. The morning of plug detection was estimated as
E0.5. Animals were sacriﬁced, and E15.5 embryos were removed
for histological and Western blot analysis.
Single Myoﬁber Isolation
Mice were killed by cervical dislocation, and EDL muscles were
carefully dissected. Muscles were digested in 0.1% collagenase
type V for 20 minutes and individual myoﬁbers were dissociated
by trituration using a Pasteur pipette [40].
For experiments in ﬂoating conditions, isolated myoﬁbers
were cultured for 24 hours in 6 or 12 wells coated with horse
serum to prevent ﬁber attachment, at 37 Ci n5 %C O 2 in a plat-
ing medium (Dulbecco’s modiﬁed Eagle’s medium [DMEM] con-
taining 10% horse serum, 0.5% chick embryo extract, 100 U/ml
penicillin, 100 lg/ml streptomycin, and 50 lg/ml gentamycin).
The ﬁbers were then switched to a proliferation medium (DMEM
containing 20% fetal bovine serum, 10% horse serum, 2% chick
embryo extract, 100 U/ml penicillin, 100 lg/ml streptomycin, and
50 lg/ml gentamycin) and incubated with the NO donors 3-mor-
pholinosydnonimine (SIN-1) or 1-[N-(2-aminoethyl)-N-(2-ammo-
nioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NO), L-NAME,
the guanylate cyclase inhibitor 1H-[1, 2, 4]oxadiazolo[4,3-a]qui-
noxalin-1-one (ODQ), 8Br-cGMP, Wnt7a, or vehicle. When used,
BrdU (14 mg/ml) was added daily starting from the day of ﬁbers
isolation [29]. Results shown are averages of three to ﬁve repro-
ducible independent experiments as indicated by the n number in
the ﬁgure legends.
Immunoﬂuorescence on Single Fibers
Single ﬁbers, freshly isolated or cultured in vitro, were ﬁxed with
4% paraformaldehyde for 30 minutes at room temperature and
incubated in PBS containing 0.1% Triton X-100 and 10% goat
serum (GS) for 30 minutes before antibody incubations in PBS
containing 1% GS overnight at 4 C. For BrdU experiments, the
ﬁbers were incubated in PBS containing 0.5% Triton X-100 and
10% GS for 30 minutes before primary antibodies incubation
[29]. The secondary antibody incubation was for 1 hour at room
temperature.
Nuclei were stained with 10 lM Hoechst 33342 for 5 minutes
at room temperature, and single ﬁbers were mounted using the
Prolong Gold antifade reagent. Results shown are averages of
three to ﬁve reproducible independent experiments as indicated
by the n number in the ﬁgure legends.
Real-Time Polymerase Chain Reaction
Analyses were carried out on single ﬁbers obtained from CTX-
injected mice 10 days after damage or from 9-month-old a-SG
null mice. RNA was prepared from freshly isolated single ﬁbers
using Trizol, and 1 lg of RNA per sample was reverse tran-
scribed into cDNA using the QuantiTect Reverse Transcription
kit according to the manufacturer’s instructions. The expression
levels of Myf5, Pax7, Wnt7a, Fzd7, Vangl2, and b-Cat were ana-
lyzed by quantitative real-time polymerase chain reaction (PCR)
on an ABI PRISM 7900HT Fast Real-Time PCR Systems using
speciﬁc gene expression assays. b2 Microglobulin and glyceralde-
hyde-3-phosphate dehydrogenase were used for normalization
with similar results. Untreated ﬁbers were used as endogenous
reference. Data were analyzed using the d-delta-Ct method.
Results shown are averages of three to ﬁve reproducible inde-
pendent experiments as indicated by the n number in the ﬁgure
legends.
198 Nitric Oxide Maintains the Satellite Cells PoolSmall Interfering RNAs’ Transfections
Silencing of Vangl2 was obtained using a small interfering RNA
(siRNA) duplex (ID s96801 and s96802) at the ﬁnal concentra-
tion of 10 nM. The speciﬁcity was determined by the analysis of
Vangl2 expression levels in myoﬁbers transiently transfected with
the speciﬁc siRNA duplex or with the scrambled control sequence
by quantitative real-time PCR [25]. Transfections were carried
out 16 hours after dissection in proliferation medium using Lipo-
fectamine 2000. Transfection efﬁciency was monitored using a
Cy3-labeled siRNA. RNA extraction or immunoﬂuorescence anal-
yses were performed 96 or 42 hours later. Results shown are
averages of three to four reproducible independent experiments as
indicated by the n number in the ﬁgure legends.
Analysis of Biochemical and Functional Parameters
in Dystrophic Mice
Serum creatine phosphokinase (CK) levels were measured in
blood samples obtained by tail vein withdrawal exactly as
described [39]. Functional muscle activity was measured using
the running wheel, to assess free locomotor activity, and the
exhaustion treadmill, to assess resistance to fatigue carried out
exactly as described [39]. Averages of results obtained in 15 ani-
mals are shown in the ﬁgures.
Immunoﬂurescence and Histology on Tissue Sections
Animals were sacriﬁced by cervical dislocation, and TA (CTX-
injected mice) or diaphragm muscles (a-SG null mice) were dis-
sected and immediately frozen in liquid N2-cooled isopentane
[39]. For histological analysis, serial muscle sections were
obtained and stained in hematoxylin and eosin (H&E) following
standard procedures. Necrotic cells were identiﬁed by hypereosi-
nophilia, thinning and waviness, and presence of many nuclei [41]
while regenerating ﬁbers were distinguished based on the central
localization of their nuclei. Pax7
þ cells were counted by immuno-
ﬂuorescence staining of muscle sections using anti-Laminin and
anti-Pax7 antibodies exactly as described [42].
In the case of embryo experiments, samples were treated and
cryosections were prepared as described [43]. All sections were
taken on the sagittal plane and the depth of cut was established at
the midline of the embryo and by using the Kaufman’s atlas of
embryology. Matched sections from at least three separate
embryos were used for all analyses. Sections were mounted using
the Prolong Gold antifade reagent. Averages of results obtained
in 15 animals are shown in the ﬁgures.
Sodium Dodecylsulfate Polyacrylamide Gel
Electrophoresis and Western Blotting
Myogenic precursor cells isolated from leg adult muscles [44] or
decapitated and eviscerated mouse embryos [43] were lysed and
analyzed by sodium-dodecylsulfate electrophoresis exactly as
described [45]. Averages of results obtained in 15 animals inde-
pendently examined are shown.
Statistical Analysis
Results are expressed as the means 6 SEM. For the parameters
with a normal distribution, the Student’s t test was used, whereas
the Mann-Whitney U test was used for parameters with a non-
normal distribution. A p value <.05 was considered as statisti-
cally signiﬁcant.
RESULTS
Nitric Oxide Affects Satellite Cells Fate
To study the effect of NO on SC fate, we analyzed Pax7 and
Myf5 cell numbers on single myoﬁbers isolated from EDL
muscle and cultured in ﬂoating conditions in the presence or
absence of the NO donor SIN-1, the NOS inhibitor L-NAME,
or vehicle. These experimental conditions maintain SC ana-
tomical location and allow their physiological transition across
the activation and self-renewal phases [4]. Single myoﬁbers
isolated from age-matched nNOS
 /  mice were analyzed in
parallel. In nonadherent culture conditions, myogenic precursor
cells became activated immediately after isolation and under-
went their ﬁrst division within 36–42 hours, generating cell
doublets that have clonal origin (Supporting Information Fig.
1A), as already described [22]. Pax7 and Myf5 expression was
evaluated after 96 hours of culture, that is, at a stage in which
Pax7
þ/Myf5
  and Pax7
 /Myf5
þ cells are considered self-
renewing or committed to ﬁnal differentiation into mature myo-
blasts, respectively [14, 19]. In our experimental conditions, all
Myf5
þ cells were also MyoD
þ and about 90% 6 3.5% of
Myf5
þ cells expressed Myogenin, a late differentiation factor
[11] (Supporting Information Fig. 1B).
SIN-1 increased, while L-NAME decreased the number of
Pax7
þ/Myf5
  cells. Consistently, the number of Pax7
þ/
Myf5
  cells in single myoﬁbers obtained from nNOS
 /  mice
was reduced (Fig. 1A and 1B). The effects of SIN-1 and
L-NAME were concentration dependent (Supporting Informa-
tion Fig. 1C).
NO donation or removal also affected the number of
Pax7
 /Myf5
þ cells that was increased by treatment with the
NO donors and reduced by L-NAME or in nNOS
 /  mice. Of
importance, such an effect was signiﬁcantly less evident than
the one observed on Pax7
þ/Myf5
  SC (1.4-fold vs. 14-fold
increase with SIN-1, Fig. 1C), indicating that NO increased pri-
marily the number of Pax7
 /Myf5
þ SC. Results similar to
those yielded by SIN-1 were obtained using a chemically unre-
lated NO donor, DETA-NO (Supporting Information Fig. 1D),
highlighting the dependence of the observed effects on NO.
NO Increases the Number of Satellite Cells after
Repetitive Cardiotoxin-Induced Muscle Damage
and Favors Muscle Regeneration
After CTX injection, SC increased in number within 2–5 days
(Supporting Information Fig. 2A). Approximately 10 days
after, SC reappeared in a sublaminar position typical of quies-
cent cells [25] (Supporting Information Fig. 2A). At this
stage, the formation of centronucleated-regenerating ﬁbers
was clearly observed (Supporting Information Fig. 2B).
We used this model to evaluate the effect of NO on
myogenic precursor cells fate in vivo and its importance for
muscle regeneration. We investigated the effect of a pharma-
cological treatment with the NO donor molsidomine, which is
converted in vivo to its active metabolite SIN-1, or with
L-NAME. Animals received three injections of CTX or vehi-
cle (PBS) at 5-day intervals. nNOS
 /  mice treated or not
with CTX were investigated in parallel. Repeated, short-haul
injury induced severe damage and reduced the number of
SC due to the repeated cycles of damage and proliferation
(Fig. 2A). The effect of NO was evaluated 10 days after
CTX treatment by assessing single myoﬁbers obtained from
EDL, histological sections of TA, and myogenic cells iso-
lated from hind limb muscles.
Single ﬁbers freshly isolated after triple challenge with
CTX from EDL of mice treated with L-NAME or from
nNOS
 /  mice exhibited a signiﬁcantly reduced number of
Pax7
þ/Myf5
  cells compared with control animals. By con-
trast, molsidomine increased the number of Pax7
þ/Myf5
 
cells in myoﬁbers (Fig. 2A, 2B, 2C). Real-time PCR
analyses of Pax7 mRNA expression in single myoﬁbers
conﬁrmed these results (Fig. 2D). Consistent with the
results reported in Figure 1, also in this case the number of
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þ/Myf5
  cells was increased by NO signiﬁcantly more
than the number of Pax7
 /Myf5
þ cells (Supporting Infor-
mation Fig. 2C, 2D).
In the histological sections, immunostaining revealed that
the number of Pax7
þ cells was increased in molsidomine-
treated animals compared with the control and reduced in
Figure 1. Nitric oxide (NO) increases the number of satellite cells in ex vivo isolated myoﬁbers. (A): Number of Pax7
þ/Myf5
  cells in single ﬁbers cul-
tured in ﬂoating conditions. Fibers were obtained from wild-type mice and treated for 96 hours with the NO donor SIN-1 (3 lM), the NOS inhibitor L-
NAME (3 mM), or vehicle (NT), or obtained from nNOS
 /  mice. Data are expressed as mean 6 SEM and normalized for ﬁber nuclei number. Results are
from at least 50 ﬁbers for each experiment, n ¼ 4; *, p   .05 versus NT. Representative images of the results reported in (A) are shown in (B). Pax7
þ cells
are green, Myf5
þ are red. Blue staining shows nuclei. Scale bar ¼ 25 lm. (C): Number of Pax7
 /Myf5
þ in single ﬁbers cultured in ﬂoating conditions.
Data are expressed as mean 6 SEM after normalization for ﬁber nuclei number. Results are from at least 50 ﬁbers for each experiment, n ¼ 4; *, p   .05
versus NT. Abbreviations: L-NAME, N
xnitro-L-arginine methylester; NT, untreated; nNOS, nitric oxide synthase; SIN-1, 3-morpholinosydnonimine.
200 Nitric Oxide Maintains the Satellite Cells PoolFigure 2. Nitric oxide (NO) increases the satellite cell pool after repeated CTX injections in vivo. (A): Number of Pax7
þ/Myf5
  cells in single
ﬁbers isolated 10 days after single or three (multiple) CTX injections. Data are expressed as mean 6 SEM and normalized for ﬁber nuclei num-
ber. At least 50 ﬁbers were analyzed for each experiment, n ¼ 3; *, p   .05 versus single damage. The number of Pax7
þ/Myf5
  cells counted in
ﬁbers isolated prior to CTX injection (untreated) or in mice receiving three (multiple) injections of PBS as control are also shown. (B): Number
of Pax7
þ/Myf5
  cells counted in single ﬁbers isolated from Extensor Digitorum Longus muscle (EDL) muscle after multiple injections of CTX.
Fibers were either obtained from wild-type mice that received STD or a diet containing the NO donor MOLS (3 mg/kg) or with L-NAME (1 mg/
ml) in drinking water, or isolated from nNOS
 /  mice. Data are expressed as mean 6 SEM ( 100 ﬁbers for each experiment, n ¼ 3) and nor-
malized for ﬁber nuclei number; *, p   .05 versus STD. (C): Representative images of data shown in (B). Pax7
þ cells are green, Myf5
þ cells
are red. Blue staining shows nuclei staining by Hoechst. Scale bar ¼ 25 lm. (D): Real-time PCR analysis of Pax7 expression in myoﬁbers iso-
lated after CTX injection. Results are from three independent experiments and are reported as fold increases over STD, set arbitrarily at 1; *, p
  .05 versus STD. (E): Number of Pax7
þ satellite cells counted in sections of isolated Tibialis Anterior (TA) muscles. Data are expressed as
mean 6 SEM and normalized for ﬁber number, n ¼ 5; *, p   .05 versus STD. (F): Representative images of Pax7-stained sections. Pax7 is
green while laminin is red. Nuclei are blue. Scale bar ¼ 75 lm. (G): Number of centronucleated ﬁbers counted in hematoxylin and eosin (H&E)
sections from TA muscles. Results are expressed as mean 6 SEM and reported as fold increases over STD, set arbitrarily at 100, n ¼ 5; *, p  
.05. (H): Representative images of H&E sections. Scale bar ¼ 100 lm. Abbreviations: CTX, cardiotoxin; L-NAME, N
xnitro-L-arginine methyl-
ester; MOLS, molsidomine; nNOS, nitric oxide synthase; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; STD, standard diet.animals that received L-NAME as well as in nNOS
 /  mice
(Fig. 2E, 2F). Consistent with this observation, molsidomine
enhanced whereas L-NAME or nNOS ablation reduced the
number of centronucleated ﬁbers, indicating that NO stimu-
lates regeneration (Fig. 2G and 2H).
Analysis of the number of myogenic cells residing in the
G0 versus G2/M phases of cell cycle at day 10 after CTX
damage conﬁrmed the above results. Myogenic cells in G0,
analyzed after exclusion of cells in the G1 phase by pyronin
staining [19], express Pax7 at signiﬁcant levels, consistent with
their nature of quiescent myogenic precursors (Supporting In-
formation Fig. 2E, 2F). Treatment with molsidomine increased
the number of cells in the G0 phase after 10 days of damage
whereas L-NAME dramatically reduced it with respect to ani-
mals receiving STD (Supporting Information Fig. 2F, 2G).
Cells isolated from nNOS
 /  mice behaved as those treated
with L-NAME (Supporting Information Fig. 2F, 2G).
These data indicate that NO, both endogenous and exoge-
nously administered, increases the pool of myogenic precursor
cell in vivo, delaying its reduction during repetitive CTX
damage and sustaining regeneration of skeletal muscle.
NO Stimulates Proliferation of Satellite Cells
Via cGMP
To investigate how NO increases the number of SC, we ana-
lyzed its effect on SC proliferation measuring BrdU incorpo-
ration in ﬁbers cultured in ﬂoating conditions in the presence
or absence of SIN-1 or L-NAME, or in ﬁbers isolated from
molsidomine- or L-NAME-treated animals.
In isolated ﬁbers treated ex vivo, SIN-1 increased while
L-NAME reduced the number of BrdU
þ SC after 72 and 96
hours of culture (Fig. 3A). Interestingly, more susceptible to
the mitogenic effect of NO were the Pax7
 /Myf5
þ differentia-
tion-determined SC (Fig. 3B), whereas the number of Pax7
þ/
Myf5
  SC was not affected. Molsidomine signiﬁcantly increased
while L-NAME reduced the number of BrdU
þ ﬁbers with
respect to ﬁbers isolated from STD-treated animals (Fig. 3C).
We investigated the cGMP dependency of the mitogenic
effect of NO by culturing single ﬁbers in ﬂoating conditions
in the presence or absence of the cell permeable analog of
cGMP, 8-Br cGMP. 8-Br cGMP increased proliferation of SC
similarly to what was observed with SIN-1 (Fig. 3D). The
mitogenic effect of 8-Br cGMP was on the Pax7
 /Myf5
þ SC
whereas it did not affect Pax7
þ/Myf5
  SC (Fig. 3E). Consis-
tently, inhibition of cGMP generation by the guanylate cyclase
inhibitor ODQ reverted the effect of SIN-1 only on Pax7
 /
Myf5
þ SC (Fig. 3D, 3E). These results indicate that stimulation
of proliferation by NO accounts for an increase in committed
SC, an event already known to occur in other cell types through
well-deﬁned pathways [46, 47]; they also indicate that other
mechanisms, independent of cGMP, are responsible for the NO-
dependent increase in Pax7
þ/Myf5
  self-renewing cells.
NO Regulates Vangl2 Expression and Enhances the
Number of Pax7
1/Myf5
2 Satellite Cells via a
cGMP-independent Mechanism
The Wnt7a/Frzd7 signaling is speciﬁcally involved in sym-
metric expansion of the quiescent myogenic precursor cells
pool [25]. In single ﬁber culture, SIN-1 and exogenously
added Wnt7a on SC increased the number of Pax7
þ/Myf5
 
cells in similar ways and no additive effects were observed
by their coadministration (Fig. 4A). Treatment with SIN-1
increased the expression of Vangl2, assessed by real-time
PCR experiments on RNA isolated from single ﬁbers main-
tained in ﬂoating conditions (Fig. 4B). By contrast, no sig-
niﬁcant modiﬁcations were induced by SIN-1 in the expres-
sion levels of Wnt7a, Frzd7, or b-Cat (Supporting
Information Fig. 3A).
To verify if the effect of NO on the number of Pax7
þ/
Myf5
  SC required Vangl2 expression, we used a Vangl2-
speciﬁc siRNAs to transfect single myoﬁbers isolated from
EDL, grown in ﬂoating condition for 96 hours and stimulated
with SIN-1. Silencing efﬁciency was about 80% (Supporting
Information Fig. 3B). Silencing of Vangl2 reduced the num-
ber of Pax7
þ/Myf5
  self-renewing cells in untreated ﬁbers as
previously described [25]; more importantly, it almost com-
pletely abolished the effect of SIN-1 (Fig. 4C). Of impor-
tance, 8-Br cGMP did not affect Vangl2 expression, demon-
strating that the action of NO on Vangl2 is independent of
cGMP generation (Fig. 4D). In the same conditions, the
cGMP-dependent increase in the number of SC was not inﬂu-
enced by Vangl2 siRNAs transfection, further conﬁrming the
existence of two separate actions of NO on SC (Fig. 4E).
We investigated whether NO signaling via Vangl2 oper-
ated also in vivo. To this end, control animals receiving a
STD, nNOS
 /  mice, and animals treated with L-NAME or
molsidomine were subjected to CTX damage. We then ana-
lyzed the expression levels of Vangl2 by real-time PCR on
single ﬁbers freshly isolated from EDL as well as protein
expression levels by Western blotting on myoblasts isolated
from limb muscles. Vangl2 levels were signiﬁcantly increased
over control in ﬁbers isolated from animals that received mol-
sidomine. Consistently, the expression of Vangl2 mRNA and
protein was reduced both in ﬁbers obtained from L-NAME-
treated animals and in nNOS
 /  mice (Fig. 4F, 4G). No
changes were observed in the expression levels of Wnt7a and
b-Cat, while Frzd7 levels were increased by NO treatment
and reduced by NO ablation (Supporting Information Fig. 3C
and not shown).
Molsidomine Maintains the Satellite Cell Pool and
Has Therapeutic Efﬁcacy in Dystrophic Mice
To examine the effects of NO on SC in muscular dystrophy,
we relied on the a-SG null mice as it has a severe dystrophic
phenotype and is a good model to assess the long-term efﬁ-
cacy of drugs active on muscular dystrophies [48]. In addi-
tion, it displays a severe depletion of the myogenic SC over
time [39]. These mice are also characterized by a functionally
inactive nNOS [37]. Animals were treated with STD or molsi-
domine from 1 month after weaning onward. The effect of
the treatment was evaluated at 5 and 9 months of age, that is,
when histological signs of muscle damage in untreated mice
are clearly visible and muscle functional activity greatly
impaired [39, 48, 49]. The number of Pax7
þ/Myf5
  SC in
single ﬁbers freshly isolated from EDL muscle of animals
receiving STD progressively decreased with age compared
with aged-matched animals (Fig. 5A). Analysis of ﬁbers iso-
lated from molsidomine-treated animals at 9 months of age
showed a signiﬁcantly higher number of Pax7
þ/Myf5
  SC
(Fig. 5B, 5C) and real-time PCR analysis of Pax7 expression
in isolated single ﬁbers conﬁrmed these results (Fig. 5D). The
number of Pax7
 /Myf5
þ-activated SC and Myf5 expression
levels were also increased by molsidomine treatment (Sup-
porting Information Fig. 4A, 4B).
Consistent with these observations, molsidomine increased
the number of the centronucleated-regenerating ﬁbers meas-
ured in diaphragm muscles (Fig. 5E, 5F) as well as the num-
ber of Pax7
þ cells (Fig. 5G). In parallel, NO enhanced the
expression of Vangl2 and Frzd7, with no changes in Wnt7a
or b-Cat levels (Fig. 5H and Supporting Information Fig. 4C).
To investigate whether molsidomine treatment led to a
functional amelioration of the muscle, we measured the CK
202 Nitric Oxide Maintains the Satellite Cells Poolserum levels, the number of necrotic ﬁbers in diaphragm mus-
cle sections, and evaluated muscle functional recovery analyz-
ing the voluntary movement and resistance to fatigue by the
free wheel and treadmill tests, respectively. Molsidomine
reduced CK serum levels (Fig. 6A) and preserved muscle in-
tegrity with reduced numbers of necrotic ﬁbers in diaphragm
muscle sections (Fig. 6B). In addition, molsidomine enhanced
signiﬁcantly spontaneous and forced motor activities indicat-
ing that not only morphological but also functional recovery
of the muscle had taken place (Fig. 6C, 6D). Thus, treatment
with molsidomine of a-SG null mice leads to a long-term
reduction of muscle damage with functional recovery.
Stem cell loss in dystrophic muscles begins already during
late embryogenesis [50]. We investigated if the beneﬁcial
effect of NO that we demonstrated in adult dystrophic mice
was observed also during embryonic and fetal myogenesis.
a-SG null female mice were treated with the molsidomine-
enriched diet or with STD during pregnancy and embryos
analyzed at day 17.5 of gestation. The expression of Pax7 in
homogenates was evaluated by Western blotting and the num-
ber of Pax7
þ cells in sections was counted after immunostain-
ing as a measure of the total myogenic stem cells content.
STD-treated a-SG null embryos displayed a reduced total
Pax7 protein content with respect to the molsidomine-treated
Figure 3. Nitric oxide (NO) stimulates satellite cells proliferation via cyclic GMP (cGMP). (A): Number of 5 bromo-20-deoxyuridine (BrdU
þ)
cells measured in single ﬁbers cultured in ﬂoating conditions for 72 or 96 hours and treated with the NO donor SIN-1 or the NOS inhibitor L-
NAME or vehicle (NT). Data are expressed as mean 6 SEM and normalized on ﬁber nuclei number. Results from at least 50 ﬁbers for each
experiment, n ¼ 4; *, p   .05 versus NT. (B): Number of cells expressing Pax7 and/or Myf5 and/or labeled by BrdU, as indicated in the caption,
in single ﬁbers cultured in ﬂoating conditions for 72 (upper) or 96 (lower) hours. Data are expressed as mean 6 SEM and normalized on ﬁber
nuclei number. Results from at least 50 ﬁbers for each experiment, n ¼ 4; *, p   .05 versus NT. (C): Number of BrdU
þ cells in single ﬁbers iso-
lated from EDL muscle of wild-type mice that received STD or a diet containing MOLS or with L-NAME in drinking water. Data are expressed
as mean 6 SEM ( 100 ﬁbers for each experiment, n ¼ 3) and normalized on ﬁber nuclei number; *, p   .05 versus STD. (D): Number of
BrdU
þ cells measured in single ﬁbers cultured in ﬂoating conditions for 72 or 96 hours and treated with SIN-1 or the cell-permeable cGMP ana-
log 8-Br cGMP (0.5 mM), SIN1 plus the inhibitor of the guanylate cyclase 1H-[1, 2, 4]oxadiazolo[4,3-a]quinoxalin-1-one (3 lM) or vehicle
(NT). Data are expressed as mean 6 SEM and normalized on ﬁber nuclei number. Results from at least 30 ﬁbers for each experiment, n ¼ 4; *,
p   .05 versus NT. (E): Number of Pax7
þ/Myf5
  and Pax7
 /Myf5
þ SC measured in single ﬁbers cultured in ﬂoating conditions for 96 hours.
Data are expressed as mean 6 SEM and normalized on ﬁber nuclei number. Results are from at least 30 ﬁbers for each experiment, n ¼ 4; *, p
  .05 versus NT. Abbreviations: L-NAME, N
xnitro-L-arginine methylester; MOLS, molsidomine; NT, untreated; nNOS, nitric oxide synthase;
SIN1, 3-morpholinosydnonimine; STD, standard diet; siRNA, small interfering RNA.
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þ/Myf5
  satellite cell numbers. (A): Number of Pax7
þ/Myf5
 
in single ﬁbers cultured in ﬂoating conditions and treated with SIN-1 or Wnt7a (25 ng/ml) alone or in combination. Vehicle-treated ﬁbers are
shown for comparison (NT). Data are expressed as mean 6 SEM and normalized on ﬁber nuclei number. At least 50 ﬁbers for each experiment,
n ¼ 4, were analyzed, *, p   .05 versus NT. (B): Real-time polymerase chain reaction (PCR) analysis of Vangl2 expression in single ﬁbers from
wild-type or from nNOS
 /  mice, cultured in ﬂoating conditions with SIN-1, L-NAME, or vehicle (NT). Results are expressed as fold changes
over the values in NT set arbitrarily at 1, n ¼ 3, *, p   .05 versus NT. (C): Number of Pax7
þ/Myf5
  SC in single ﬁbers treated with SIN-1 or
vehicle (NT) and transfected with scramble sequence or with the Vangl2 siRNAs (siRNA). Data are expressed as mean 6 SEM and normalized
on ﬁber nuclei number. Number of ﬁbers analyzed was  50 for each treatment, n ¼ 3, *, p   .05 versus NT; #, p   .05 versus scramble-trans-
fected SIN-1 treated ﬁbers. (D): Real-time PCR analysis of Vangl2 expression in single ﬁbers cultured in ﬂoating conditions and treated with
SIN-1, 8-Br cGMP, or vehicle (NT). Results are expressed as fold changes over the values in NT set arbitrarily at 1, n ¼ 3, *, p   .05 versus
NT. (E): Number of Pax7
 /Myf5
þ SC in single ﬁbers. Data are expressed as mean 6 SEM and normalized on ﬁber nuclei number. The number
of ﬁbers analyzed was  50 for each treatment, n ¼ 3, *, p   .05 versus NT. (F): Real-time PCR analysis of Vangl2 expression in myoﬁbers iso-
lated after CTX injection. Fibers were from wild-type mice that received STD or a diet containing the NO donor MOLS or with L-NAME in
drinking water, or isolated from nNOS
 /  mice. Results are expressed as fold changes over the values in STD set arbitrarily at 1, n ¼ 3, *, p  
.05 versus STD. (G): Western blotting data showing expression of Vangl2 protein and a-tubulin, used as loading control, in lysates of myoblasts
isolated from limb muscles, n ¼ 3. *, p   .05 versus STD. Representative images are shown in the inset (lane 1: STD, lane 2: MOLS, lane 3: L-
NAME, lane 4: nNOS
 /). Abbreviations: NT, untreated; L-NAME, N
xnitro-L-arginine methylester; MOLS, molsidomine; nNOS, nitric oxide syn-
thase; siRNA, small interfering RNA; SIN-1, 3-morpholinosydnonimine; STD, standard diet.Figure 5. MOLS delays the reduction of the satellite cell pool in dystrophic mice. (A): Number of Pax7
þ/Myf5
  cells counted in single ﬁbers
isolated from a-SG null mice at 2, 5, or 10 months of age, compared with wild-type mice. Data are expressed as mean 6 SEM and normalized
on ﬁber nuclei number. Fiber number was  100, n ¼ 3, *, p   .05 versus 5 months. (B, C): Representative images and number of Pax7
þ/Myf5
 
cells counted in single ﬁbers isolated from a-SG null mice that received STD or treatment with MOLS. Data are expressed as mean 6 SEM and
normalized on ﬁber nuclei number. Fiber number was  100, n ¼ 3, *, p   .05 versus STD. Images in (B) show the staining for Pax7 (green),
Myf5
þ (red), and nuclei (Hoechst, blue). Scale bar ¼ 75 lm. (D): Real-time polymerase chain reaction (PCR) analysis of Pax7 expression in
myoﬁbers isolated from a-SG null mice treated with STD or MOLS. Results are expressed as fold changes over the values in STD set arbitrarily
at 1, n ¼ 3, *, p   .05 versus STD. (E): Number of centronucleated ﬁbers counted in hematoxylin and eosin sections (representative images in
F) and number of Pax7
þ SC (G) in isolated diaphragm muscles of a-SG null mice. Data are expressed as mean 6 SEM and normalized on the
section area, n ¼ 15. *, p   .05 versus STD. Scale bar ¼ 100 lM. (H): Real-time PCR analysis of Vangl2 expression in ﬁbers isolated from a-
SG null mice treated with STD or MOLS. Results are expressed as fold changes over the values in STD set arbitrarily at 1, n ¼ 3, *, p   .05
versus STD. Abbreviations: MOLS, molsidomine; a-SG, a-sarcoglycan; STD, standard diet; WT, wild type.
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strated a recovery of Pax7
þ cell loss in a-SG null NO-treated
embryos (Fig. 7B, 7C). Thus molsidomine has beneﬁcial
effects also during embryonic myogenesis of a-SG null mice.
DISCUSSION
In this study, we demonstrate that NO controls SC number
and fate in such a way that it prevents the exhaustion of the
reserve pool of these cells under conditions of severe muscle
damage. We found that regulation by NO of SC number and
fate is physiological, as inhibition or genetic ablation of
nNOS in ﬁbers is per se sufﬁcient to induce a progressive
reduction of the regenerative capacity of muscles. NO stimu-
lated proliferation of SC via generation of cGMP and
increased the number of Pax7
þ/Myf5
  SC via a cGMP-inde-
pendent pathway. These actions appear coordinated to
increase SC number per ﬁber.
The cGMP-dependent effect on proliferation is in line
with previous reports about the mitogenic action of NO, for
which the effectors downstream of cGMP have been identiﬁed
[46, 47, 51]. The second mechanism, independent of cGMP,
is instead new and found to require the noncanonical Wnt
pathway and speciﬁcally Vangl2. NO enhanced the expression
of Vangl2 while Vangl2 silencing completely abolished the
action of NO. Thus, while we cannot exclude that other
downstream effectors of NO participated in its effect on
Pax7
þ/Myf5
  SC expansion, our results identify Vangl2 as
necessary for this action of NO.
Vangl2 regulates planar cell polarity and the converged-
extension movements in gastrulation and neurulation, as well
as cell adhesion, motility, polarity, and gene transcription in a
RhoA-dependent way; Vangl2 null mice do not survive past
birth and show developmental defects in the nervous, cardio-
vascular, skeletal, and vestibular systems [52–54].
Despite its relevance in development, little is known on
the functional role of Vangl2 and the noncanonical Wnt path-
way in myogenesis, apart from recent evidence of its role in
symmetric cell division and expansion of the quiescent SC
pool, inﬂuencing the distribution and expression of members
of the planar cell polarity pathway [25]. In addition, the non-
canonical Wnt pathway plays a role in differential activation
of genes in epaxial or hypaxial progenitors, via the action of
protein kinase C (PKC) [55, 56]. The identiﬁcation of an
interplay between NO signaling and the Vangl2/noncanonical
Wnt pathway in SC self-renewal, and the demonstration of
the functional and therapeutic relevance of such an effect,
extend the importance of this pathway in muscle and other
tissues. The action of NO on noncanonical Wnt signaling was
to date limited to its role in the control of cell division, mor-
phogenesis, and cell movement/polarity during early Xenopus
development [57], and in the regulation of c-Jun N-terminal ki-
nase (JNK)/stress-activated protein kinase–related SC move-
ments in ﬁbers [58]. Several of the components of the nonca-
nonical Wnt pathway, for example, RhoA, JNK, and PKC,
have however already been shown to be regulated by NO in a
variety of different cell systems, although a connection with
this speciﬁc pathway was not established [59–61]. Thus the
possibility that the Vangl2/noncanonical Wnt pathway partici-
pates to these other actions of NO should be investigated.
The observation that the Vangl2/noncanonical Wnt path-
way is activated by NO and is involved in the NO-driven SC
regulation and muscle repair also suggests that the role of NO
in skeletal muscle is broader than previously envisaged. First,
we demonstrate that the action of NO is crucial not only in
Figure 6. Nitric oxide induces functional recovery in dystrophic mice. CK plasma levels (A), number of necrotic ﬁbers counted in hematoxylin
and eosin sections of isolated Tibialis Anterior (B), free wheel running (C), and treadmill test results (D) measured in a-sarcoglycan null mice
that received STD or treatment with MOLS. Data are expressed as mean 6 SEM, n ¼ 15, *, p   .05 versus STD. Abbreviations: CK, creatine
phosphokinase; MOLS, molsidomine; STD, standard diet.
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also during embryonic myogenesis. This might lead to a re-
evaluation of the role of NO in early myogenesis, in which
the role of this messenger has been poorly investigated to
date. In addition, some of the actions through which NO acts
to regulate adult muscle function are independent of cGMP
but the precise effectors have not always been identiﬁed [33,
34, 62, 63]. Assessment of the involvement in these events of
NO-dependent Wnt-signaling would lead to a better under-
standing of its contribution to skeletal muscle physiology.
The importance of these data goes beyond muscle physiol-
ogy and has important consequences for the therapy of mus-
cular dystrophy. The maintenance of the SC endogenous pool
is crucial to the therapy of muscular dystrophy, a disease in
which the continuous myoﬁber damage leads to repeated
rounds of degeneration and repair that cause the progressive
fall of SC regenerative ability [11].
To date an effective pharmacological strategy to muscular
dystrophy is still lacking and the only available therapeutic
protocols, based on corticosteroids are not resolutive and asso-
ciated with severe side effects [64]. The recent approaches to
muscular dystrophy therapy based on stem cell delivery [65,
66] and exon skipping [67, 68] are promising; however, they
are expensive and in some cases are useful for only subsets of
patients. Pharmacological strategies targeting key events down-
stream of the genetic defect can compensate in several genetic
diseases, at least partially, the pathological consequence of the
genetic defect and have therapeutic potential; in addition, they
are cost effective and of broad applicability [69].
NO delivery was considered a possible therapeutic strat-
egy based on the fact that mislocalization of nNOSl and
reduction of its activity due to dystrophin complex destruction
contribute to damage progression [35–38], and that restoration
of NO signaling by nNOS overexpression ameliorates muscle
function [70, 71]. Indeed some NO donors were found to limit
muscle damage and to gain therapeutic efﬁcacy in combina-
tion therapies with non steroidal anti-inﬂammatory drugs [39,
49, 72] or corticosteroids [73].
The role of NO in myogenesis has been consequently
intensely investigated and the messenger has been reported to
promote activation, differentiation, and fusion of SC via vari-
ous mechanisms [74–80]. In addition, NO is a vasodilator and
Figure 7. Nitric oxide reduces stem cell loss in dystrophic muscles during late embryogenesis. (A): Western blot analysis of Pax7 expression
and of a-tubulin used as an internal control in homogenates of a-sarcoglycan null embryos from pregnant mothers receiving STD or treatment
with MOLS. The left panel shows a representative Western blot, the right graph the Pax7 expression values, normalized against a-tubulin expres-
sion, n ¼ 15, *, p   .05 versus STD. (B): Representative images of Pax7 immunostaining of embryo intercostal sections obtained from the same
groups of embryos. Pax7 staining is in red while nuclei are in blue. Scale bar ¼ 75 lm. (C): Number of intercostal myoblasts expressing Pax7
counted in embryo intercostal sections obtained from the same groups of embryos. Data are expressed as mean 6 SEM, n ¼ 15, *, p   .05 ver-
sus STD. Abbreviations: MOLS, molsidomine; STD, standard diet.
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ute to the therapeutic action of NO in dystrophy. Indeed,
increasing the vasculature in muscular dystrophy ameliorates
the histological and functional phenotypes associated with this
disease [81]. Nonetheless, none of these actions, while impor-
tant, appear sufﬁcient to explain the long-term efﬁcacy of NO-
based therapies. Although we have not clariﬁed whether and
by which cellular mechanism(s) NO increases cycling lifetime
of SC, the NO-dependent increased proliferation of SC may
allow an increased number of these cells to enter the self-
renewal pathway, rather than into immediate myogenic differ-
entiation. This mechanism may explain why NO is effective
long-term in the chronic muscle degeneration observed in mus-
cular dystrophy and further supports its therapeutic role.
A previous short-term study in the mdx mouse model of
dystrophy showed that molsidomine reduces creatine kinase se-
rum levels, muscle necrosis as well as the fatty and connective
tissue inﬁltrates [82]. We now demonstrate that molsidomine is
signiﬁcantly effective long-term and per se, also on muscle func-
tion and recovery, and in such a severe model of dystrophy as
the a-SG null mouse. This ﬁnding enhances the possibility of
optimizing NO-based therapies. Why molsidomine is more
effective than the other NO donors tested so far remains to be
established. A likely possibility is that molsidomine is particu-
larly effective in increasing SC number. Such an action may
depend on the pharmacokinetic proﬁle of NO release by molsi-
domine, or on the fact that it releases alongside NO also biologi-
cally active nitrites and nitrates [83]. These compounds appear
to have beneﬁcial functions in skeletal muscle [84, 85].
CONCLUSION
Our results identify NO as a key messenger in SC fate regula-
tion and expand the signiﬁcance of the Vangl2-dependent
Wnt noncanonical pathway in myogenesis. The demonstration
that molsidomine prevents the decrease of SC under patholog-
ical conditions with long-term functional improvement of
muscle function reinforces the notion that optimizing NO-
based strategies for muscular dystrophy is a valuable path-
ways to pursue in therapeutic perspective.
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